Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Core Insights - Genelux Corporation has initiated the Phase 2 (VIRO-25) trial for Olvi-Vec in recurrent non-small cell lung cancer (NSCLC) patients who have failed previous treatments, marking a significant milestone for patients with limited options [1][2] - The trial aims to evaluate the efficacy and safety of Olvi-Vec combined with platinum-doublet chemotherapy and a physician's choice of immune checkpoint inhibitor (ICI) compared to docetaxel [2] - Interim results from the trial are expected to be available by mid-2025 [1][2] Company Overview - Genelux Corporation is a late-stage clinical biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive solid tumors [4] - The company's lead product candidate, Olvi-Vec, is a modified strain of the vaccinia virus, currently being evaluated in multiple clinical trials, including a Phase 3 trial for platinum-resistant ovarian cancer [4] - Olvi-Vec has been administered to over 150 patients across seven clinical trials, demonstrating a generally well-tolerated safety profile and evidence of clinical benefit [3] Product Details - Olvi-Vec is a proprietary oncolytic vaccinia virus with a large engineering capacity, designed to infect and kill various tumor cell types while eliciting an anti-tumor immune response [3] - The ongoing Phase 1b/2 trial for intravenous delivery of Olvi-Vec in recurrent small cell lung cancer is co-sponsored with Newsoara Biopharma Co. Ltd., highlighting the potential of Olvi-Vec as a systemically administered treatment option [2]